Coherus BioSciences (CHRS) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.41 --0%
EPS Growth %: +23.5%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
DGICA, NEXT, REPL, More
EPS Growth %: +23.5%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
DGICA, NEXT, REPL, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $12.31 million versus the consensus estimate of $14.43 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb raises annual outlook as Q2 tops estimates; shares up
- Lincoln Electric (LECO) Tops Q2 EPS by 13c, Beats on Revenue
- Hilton Grand Vacations (HGV) Misses Q2 EPS by 20c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
